SutroVax, a Sutro Biopharma spin-out that also counts Johnson & Johnson as an investor, will use the series A capital to further develop its biopharmaceutical vaccines.
US-based vaccine developer SutroVax raised $22m in a series A round led by venture capital firm Abingworth and backed by pharmaceutical company Roche’s corporate venturing unit, Roche Venture Fund, yesterday.
Investment firm Longitude Capital and VC firm CTI Life Sciences Fund also participated in the round.
SutroVax, which was spun out of biopharmaceutical company Sutro Biopharma in January 2014, is developing vaccines for infectious diseases. The series A funding will be used to advance several of the company’s vaccine candidates…
